Physician profile
Andres Serrano
NPI 1336354562
$1,948.78
in general payments reported to CMS, 2019-2025
18 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $129 · 2021: $175 · 2022: $246 · 2023: $66.11 · 2024: $418 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882 · Education: $53.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.78 |
| Education | $53.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $596.75 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $203.29 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $169.52 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $139.21 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $129.64 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $122.02 | 2019 | |
| Vantive US Healthcare LLC | $84.04 | 2025 | Renal - Amia |
| Akebia Therapeutics INC | $79.03 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $76.38 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $70.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.13 | 2024-2025 | Jardiance |
| Baxter Healthcare | $60.04 | 2019 | |
| Lilly USA, LLC | $39.70 | 2024-2025 | Jardiance |
| Alcon Vision LLC | $29.37 | 2021 | |
| Aurinia Pharma U.S., INC. | $28.03 | 2023 | Lupkynis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $25.00 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $15.49 | 2025 | |
| Merck Sharp & Dohme LLC | $14.90 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.